Skip to main content

08.06.2018 | Breast Oncology | Ausgabe 9/2018

Annals of Surgical Oncology 9/2018

Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial

Annals of Surgical Oncology > Ausgabe 9/2018
MD Walter Paul Weber, MD Christoph Tausch, PhD Stefanie Hayoz, MD Mathias Konrad Fehr, PhD Karin Ribi, MD Hanne Hawle, PhD Judith Eva Lupatsch, PhD Klazien Matter-Walstra, MD Federica Chiesa, MD Konstantin Johannes Dedes, MD Gilles Berclaz, MD Loic Lelièvre, MD Thomas Hess, MD Uwe Güth, MD Verena Pioch, MD Dimitri Sarlos, MD Cornelia Leo, MD Claudia Canonica, MD Natalie Gabriel, MD Jasmin Zeindler, PhD Estelle Cassoly, PhD Christiane Andrieu, MD Savas Deniz Soysal, MD Thomas Ruhstaller, MD Peter Martin Fehr, MD, PhD Michael Knauer, for the Swiss Group for Clinical Cancer Research (SAKK)
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1245/​s10434-018-6556-9) contains supplementary material, which is available to authorized users.
This work has been presented orally at the 71st Annual Cancer Symposium of the Society of Surgical Oncology (SSO), Chicago, IL, March 23, 2018.



Several studies and a meta-analysis showed that fibrin sealant patches reduced lymphatic drainage after various lymphadenectomy procedures. Our goal was to investigate the impact of these patches on drainage after axillary dissection for breast cancer.


In a phase III superiority trial, we randomized patients undergoing breast-conserving surgery at 14 Swiss sites to receive versus not receive three large TachoSil® patches in the dissected axilla. Axillary drains were inserted in all patients. Patients and investigators assessing outcomes were blinded to group assignment. The primary endpoint was total volume of drainage.


Between March 2015 and December 2016, 142 patients were randomized (72 with TachoSil® and 70 without). Mean total volume of drainage in the control group was 703 ml [95% confidence interval (CI) 512–895 ml]. Application of TachoSil® did not significantly reduce the total volume of axillary drainage [mean difference (MD) −110 ml, 95% CI −316 to 94, p = 0.30]. A total of eight secondary endpoints related to drainage, morbidity, and quality of life were not improved by use of TachoSil®. The mean total cost per patient did not differ significantly between the groups [34,253 Swiss Francs (95% CI 32,625–35,880) with TachoSil® and 33,365 Swiss Francs (95% CI 31,771–34,961) without, p = 0.584]. In the TachoSil® group, length of stay was longer (MD 1 day, 95% CI 0.3–1.7, p = 0.009), and improvement of pain was faster, although the latter difference was not significant [2 days (95% CI 1–4) vs. 5.5 days (95% CI 2–11); p = 0.2].


TachoSil® reduced drainage after axillary dissection for breast cancer neither significantly nor relevantly.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf

Weitere Produktempfehlungen anzeigen
Nur für berechtigte Nutzer zugänglich
Über diesen Artikel

Weitere Artikel der Ausgabe 9/2018

Annals of Surgical Oncology 9/2018 Zur Ausgabe
  1. Sie können e.Med Chirurgie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Chirurgie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.